Cancer specificity of promoters of the genes controlling cell proliferation

Journal of Cellular Biochemistry

Volumn 116, Issue 2, 2015, Pages 299-309

  Kashkin, Kirill ^a   Chernov, Igor ^a   Stukacheva, Elena ^a   Monastyrskaya, Galina ^a   Uspenskaya, Natalya ^a   Kopantzev, Eugene ^a   Sverdlov, Eugene ^a,b  

^a SHEMYAKIN OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY   (Russian Federation)

^b INSTITUTE OF MOLECULAR GENETICS   (Russian Federation)

Author keywords

Cancer gene therapy; Cancer specific; Cell proliferation; Promoter

Indexed keywords

CELL CYCLE PROTEIN 6; MINICHROMOSOME MAINTENANCE PROTEIN 2; POLO LIKE KINASE 1; CDC6 PROTEIN, HUMAN; CELL CYCLE PROTEIN; CKS1B PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE; DNA DIRECTED DNA POLYMERASE GAMMA; MCM2 PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; POLD1 PROTEIN, HUMAN; POLO-LIKE KINASE 1; PROTEIN SERINE THREONINE KINASE;

ARTICLE; CANCER CELL; CANCER CELL LINE; CANCER GENE THERAPY; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SPECIFICITY; CKS1B GENE; CONTROLLED STUDY; GENE; GENE EXPRESSION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HYPOTHESIS; MOLECULAR CLONING; NEOPLASM; NORMAL HUMAN; POLD1 GENE; PROMOTER REGION; REGULATOR GENE; REPORTER GENE; ANIMAL; CELL CULTURE; FIBROBLAST; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETIC TRANSFECTION; GENETICS; HEPG2 CELL LINE; METABOLISM; MOUSE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ANIMALS; CDC2-CDC28 KINASES; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; DNA POLYMERASE III; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HEP G2 CELLS; HUMANS; MICE; MINICHROMOSOME MAINTENANCE COMPLEX COMPONENT 2; NEOPLASMS; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION;

EID: 84916625040     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24968     Document Type: Article

References (49)

1. Adams RLP. 1980. Cell Culture for Biochemists. Elsevier/North-Holland: Biomedical Press. p 292.
2. Alekseenko IV, Pleshkan VV, Kopantzev EP, Stukacheva EA, Chernov IP, Vinogradova TV, Sverdlov ED. 2012. Activity of the upstream component of tandem TERT/survivin promoters depends on features of the downstream component. PLoS One 7:e46474.
3. Bochman ML, Schwacha A. 2009. The Mcm complex: Unwinding the mechanism of a replicative helicase. Microbiol Mol Biol Rev 73:652-683.
4. Borlando LR, Mendez J. 2008. CDC6: From DNA replication to cell cycle checkpoints and oncogenesis Carcinogenesis 29:237-243.
5. Chen JS, Liu JC, Shen L, Rau KM, Kuo HP, Li YM, Shi D, Lee YC, Chang KJ, Hung MC. 2004. Cancer-specific activation of the survivin promoter and its potential use in gene therapy. Cancer Gene Ther 11:740-747.
6. Chomczynski P, Sacchi N. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159.
7. Davies PC, Lineweaver CH. 2011. Cancer tumors as Metazoa 1.0: Tapping genes of ancient ancestors. Phys Biol 8:015001.
8. Djebali S, Davis CA, Merkel A, Dobin A, Lassmann T, Mortazavi A, Tanzer A, Lagarde J, Lin W, Schlesinger F, Xue C, Marinov GK, Khatun J, Williams BA, Zaleski C, Rozowsky J, Roder M, Kokocinski F, Abdelhamid RF, Alioto T, Antoshechkin I, Baer MT, Bar NS, Batut P, Bell K, Bell I, Chakrabortty S, Chen X, Chrast J, Curado J, Derrien T, Drenkow J, Dumais E, Dumais J, Duttagupta R, Falconnet E, Fastuca M, Fejes-Toth K, Ferreira P, Foissac S, Fullwood MJ, Gao H, Gonzalez D, Gordon A, Gunawardena H, Howald C, Jha S, Johnson R, Kapranov P, King B, Kingswood C, Luo OJ, Park E, Persaud K, Preall JB, Ribeca P, Risk B, Robyr D, Sammeth M, Schaffer L, See LH, Shahab A, Skancke J, Suzuki AM, Takahashi H, Tilgner H, Trout D, Walters N, Wang H, Wrobel J, Yu Y, Ruan X, Hayashizaki Y, Harrow J, Gerstein M, Hubbard T, Reymond A, Antonarakis SE, Hannon G, Giddings MC, Ruan Y, Wold B, Carninci P, Guigo R, Gingeras TR. 2012. Landscape of transcription in human cells. Nature 489:101-108.
9. Dorer DE, Nettelbeck DM. 2009. Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis. Adv Drug Deliv Rev 61:554-571.
10. Gerstein MB, Kundaje A, Hariharan M, Landt SG, Yan KK, Cheng C, Mu XJ, Khurana E, Rozowsky J, Alexander R, Min R, Alves P, Abyzov A, Addleman N, Bhardwaj N, Boyle AP, Cayting P, Charos A, Chen DZ, Cheng Y, Clarke D, Eastman C, Euskirchen G, Frietze S, Fu Y, Gertz J, Grubert F, Harmanci A, Jain P, Kasowski M, Lacroute P, Leng J, Lian J, Monahan H, O'Geen H, Ouyang Z, Partridge EC, Patacsil D, Pauli F, Raha D, Ramirez L, Reddy TE, Reed B, Shi M, Slifer T, Wang J, Wu L, Yang X, Yip KY, Zilberman-Schapira G, Batzoglou S, Sidow A, Farnham PJ, Myers RM, Weissman SM, Snyder M. 2012. Architecture of the human regulatory network derived from ENCODE data. Nature 489:91-100.
11. Gu J, Fang B. 2003. Telomerase promoter-driven cancer gene therapy. Cancer Biol Ther 2:S64-S70.
12. Guida T, Salvatore G, Faviana P, Giannini R, Garcia-Rostan G, Provitera L, Basolo F, Fusco A, Carlomagno F, Santoro M. 2005. Mitogenic effects of the up-regulation of minichromosome maintenance proteins in anaplastic thyroid carcinoma. J Clin Endocrinol Metab 90:4703-4709.
13. Hateboer G, Wobst A, Petersen BO, Le Cam L, Vigo E, Sardet C, Helin K. 1998. Cell cycle-regulated expression of mammalian CDC6 is dependent on E2F. Mol Cell Biol 18:6679-6697.
14. Heintzman ND, Hon GC, Hawkins RD, Kheradpour P, Stark A, Harp LF, Ye Z, Lee LK, Stuart RK, Ching CW, Ching KA, Antosiewicz-Bourget JE, Liu H, Zhang X, Green RD, Lobanenkov VV, Stewart R, Thomson JA, Crawford GE, Kellis M, Ren B. 2009. Histone modifications at human enhancers reflect global cell-type-specific gene expression. Nature 459:108-112.
15. Heintzman ND, Ren B. 2009. Finding distal regulatory elements in the human genome. Curr Opin Genet Dev 19:541-549.
16. Jin F, Fondell JD. 2009. A novel androgen receptor-binding element modulates Cdc6 transcription in prostate cancer cells during cell-cycle progression. Nucleic Acids Res 37:4826-4838.
17. Kashkin KN, Chernov IP, Stukacheva EA, Kopantzev EP, Monastyrskaya GS, Uspenskaya NY, Sverdlov ED. 2013. Cancer specificity of promoters of the genes involved in cell proliferation control. Acta Naturae 5:79-83.
18. Kopantzev EP, Vayshlya NA, Kopantseva MR, Egorov VI, Pikunov M, Zinovyeva MV, Vinogradova TV, Zborovskaya IB, Sverdlov ED. 2010. Cellular and molecular phenotypes of proliferating stromal cells from human carcinomas. Br J Cancer 102:1533-1540.
19. Krishnan A, Nair SA, Pillai MR. 2010. Loss of cks1 homeostasis deregulates cell division cycle. J Cell Mol Med 14:154-164.
20. Landolin JM, Johnson DS, Trinklein ND, Aldred SF, Medina C, Shulha H, Weng Z, Myers RM. 2010. Sequence features that drive human promoter function and tissue specifi city. Genome Res 20:890-898.
21. Lange SS, Takata K, Wood RD. 2011. DNA polymerases and cancer. Nat Rev Cancer 11:96-110.
22. Lenhard B, Sandelin A, Carninci P. 2012. Metazoan promoters: emerging characteristics and insights into transcriptional regulation. Nat Rev Genet 13:233-245.
23. Li B, Lee MY. 2001. Transcriptional regulation of the human DNA polymerase delta catalytic subunit gene POLD1 by p53 tumor suppressor and Sp1. J Biol Chem 276:29729-29739.
24. Lin DC, Zhang Y, Pan QJ, Yang H, Shi ZZ, Xie ZH, Wang BS, Hao JJ, Zhang TT, Xu X, Zhan QM, Wang MR. 2011. PLK1 Is transcriptionally activated by NF-kappaB during cell detachment and enhances anoikis resistance through inhibiting beta-catenin degradation in esophageal squamous cell carcinoma. Clin Cancer Res 17:4285-4295.
25. Mallik I, Davila M, Tapia T, Schanen B, Chakrabarti R. 2008. Androgen regulates Cdc6 transcription through interactions between androgen receptor and E2F transcription factor in prostate cancer cells. Biochim Biophys Acta 1783:1737-1744.
26. McKenzie L, King S, Marcar L, Nicol S, Dias SS, Schumm K, Robertson P, Bourdon JC, Perkins N, Fuller-Pace F, Meek DW. 2010. P53-dependent repression of polo-like kinase-1 (PLK1). Cell Cycle 9:4200-4212.
27. Merlo LM, Pepper JW, Reid BJ, Maley CC. 2006. Cancer as an evolutionary and ecological process. Nat Rev Cancer 6:924-935.
28. Mityaev MV, Kopantzev EP, Buzdin AA, Vinogradova TV, Sverdlov ED. 2010. Enhancer element potentially involved in human survivin gene promoter regulation in lung cancer cell lines. Biochemistry (Mosc) 75:182-191.
29. Noble D. 2012. A theory of biological relativity: no privileged level of causation. Interface Focus 2:55-64.
30. Ramakers C, Ruijter JM, Deprez RH, Moorman AF. 2003. Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data. Neurosci Lett 339:62-66.
31. Ray S, Pollard JW. 2012. KLF15 negatively regulates estrogen-induced epithelial cell proliferation by inhibition of DNA replication licensing. Proc Natl Acad Sci U S A 109:E1334-E1343.
32. Robles LD, Frost AR, Davila M, Hutson AD, Grizzle WE, Chakrabarti R. 2002. Down-regulation of Cdc6, a cell cycle regulatory gene, in prostate cancer. J Biol Chem 277:25431-25438.
33. Rother K, Li YY, Tschop K, Kirschner R, Muller GA, Mossner J, Engeland K. 2007. Expression of cyclin-dependent kinase subunit 1 (Cks1) is regulated during the cell cycle by a CDE/CHR tandem element and is downregulated by p53 but not by p63 or p73. Cell Cycle 6:853-862.
34. Segal E, Widom J. 2009. From DNA sequence to transcriptional behaviour: A quantitative approach. Nat Rev Genet 10:443-456.
35. Sharma N, Dey P. 2011. Cell cannibalism and cancer. Diagn Cytopathol 39:229-233.
36. Song B, Liu XS, Liu X. 2012. Polo-like kinase 1 (Plk1): An Unexpected Player in DNA Replication. Cell Div 7:3.
37. Song N, Zhu X, Shi L, An J, Wu Y, Sang J. 2009. Identification and functional analysis of a CDE/CHR element in the POLD1 promoter. Sci China C Life Sci 52:551-559.
38. Soussi T, Wiman KG. 2007. Shaping genetic alterations in human cancer: The p53 mutation paradigm. Cancer Cell 12:303-312.
39. Spitz F, Furlong EE. 2012. Transcription factors: From enhancer binding to developmental control. Nat Rev Genet 13:613-626.
40. Suzuki Y, Yamashita R, Shirota M, Sakakibara Y, Chiba J, Mizushima-Sugano J, Nakai K, Sugano S. 2004. Sequence comparison of human and mouse genes reveals a homologous block structure in the promoter regions. Genome Res 14:1711-1718.
41. Taylor MS, Kai C, Kawai J, Carninci P, Hayashizaki Y, Semple CA. 2006. Heterotachy in mammalian promoter evolution. PLoS Genet 2:e30.
42. Uchiumi T, Longo DL, Ferris DK. 1997. Cell cycle regulation of the human polo-like kinase (PLK) promoter. J Biol Chem 272:9166-9174.
43. Visel A, Rubin EM, Pennacchio LA. 2009. Genomic views of distant-acting enhancers. Nature 461:199-205.
44. Yew NS, Wysokenski DM, Wang KX, Ziegler RJ, Marshall J, McNeilly D, Cherry M, Osburn W, Cheng SH. 1997. Optimization of plasmid vectors for high-level expression in lung epithelial cells. Hum Gene Ther 8:575-584.
45. Zhang Y, Luoh SM, Hon LS, Baertsch R, Wood WI, Zhang Z. 2007. GeneHub-GEPIS: Digital expression profiling for normal and cancer tissues based on an integrated gene database. Nucleic Acids Res 35:W152-W158.
46. Zhao L, Chang LS. 1997. The human POLD1 gene. Identification of an upstream activator sequence, activation by Sp1 and Sp3, and cell cycle regulation. J Biol Chem 272:4869-4882.
47. Zhou C, Jong A. 1990. CDC6 mRNA fluctuates periodically in the yeast cell cycle. J Biol Chem 265:19904-19909.
48. Zhu H, Chang BD, Uchiumi T, Roninson IB. 2002. Identification of promoter elements responsible for transcriptional inhibition of polo-like kinase 1 and topoisomerase IIalpha genes by p21(WAF1/CIP1/SDI1). Cell Cycle 1:59-66.
49. Zhu ZB, Makhija SK, Lu B, Wang M, Kaliberova L, Liu B, Rivera AA, Nettelbeck DM, Mahasreshti PJ, Leath CA, Barker S, Yamaoto M, Li F, Alvarez RD, Curiel DT. 2004. Transcriptional targeting of tumors with a novel tumor-specific survivin promoter. Cancer Gene Ther 11:256-262.